Tokyo ― Terumo Corporation (TSE: 4543 Section 1) today announced that in the meeting of the board of directors held on March 27, 2014, it was decided to newly elect two persons as members of the board of directors as below. The new appointments will be confirmed at the annual general meeting of shareholders on June 24, 2014.
David Perez
(Present Position: Senior Executive Officer, President & CEO, Terumo BCT, Inc., Chairman of the Board, Terumo Global Blood Management Business)
(Notice) Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts on projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. The market share information in this press release is partly derived from our own independent research.
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).
TERUMO CORPORATION 
